

IN THE CLAIMS

1-26. (cancelled)

27. (new) A human or humanized antibody having the binding specificity of the IK17 antibody.

28. (new) The antibody as in claim 1, wherein the antibody is selected from the group consisting of: a monoclonal antibody (MAb) or fragment thereof, a fragment antibody (FAb), and a single chain fragment (scFv).

29. (new) A human or humanized antibody, said antibody being specific for oxidation specific epitopes present in a core of atherosclerotic plaques, oxidized low density lipoprotein (OxLDL) and malondialdehyde low density lipoprotein (MDA-LDL), and binds such epitopes *in vivo* at a detectably higher rate than normal tissue.

30. (new) The antibody as in claim 3, wherein the antibody is selected from the group consisting of: a monoclonal antibody (MAb) or fragment thereof, a fragment antibody (FAb), and a single chain fragment (scFv).

31. (new) A human or humanized antibody wherein the antibody comprises a variable light chain encoded by a nucleotide sequence of SEQ ID 1 and a variable heavy chain encoded by a nucleotide sequence of SEQ ID 2.

32. (new) The antibody as in claim 5, wherein the antibody is selected from the

group consisting of: a monoclonal antibody (MAb) or fragment thereof, a fragment antibody (FAb), and a single chain fragment (scFv).